Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial

The Lancet Oncology

Volumn 13, Issue 7, 2012, Pages 734-742

  Paterson, Alexander H G ^a,d   Anderson, Stewart J ^a,e   Lembersky, Barry C ^a,f   Fehrenbacher, Louis ^a,g   Falkson, Carla I ^a,h,i   King, Karen M ^a,j   Weir, Lorna M ^a,k   Brufsky, Adam M ^a,f   Dakhil, Shaker ^a,l   Lad, Thomas ^a,m   Baez Diaz, Luis ^a,n   Gralow, Julie R ^b,o   Robidoux, André ^a,p   Perez, Edith A ^c,q   Zheng, Ping ^a,n   Geyer, Charles E ^a,r   Swain, Sandra M ^a,s   Costantino, Joseph P ^a,e   Mamounas, Eleftherios P ^a,t   Wolmark, Norman ^a,u  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MAYO CLINIC   (United States)

^d TOM BAKER CANCER CENTRE   (Canada)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g KAISER PERMANENTE   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ Eastern Cooperative Oncology Group (ECOG)   (United States)

^j CROSS CANCER INSTITUTE   (Canada)

^k BRITISH COLUMBIA CANCER AGENCY   (Canada)

^l Cancer Center of Kansas   (United States)

^m Stroger Hospital Cook County MBCCOP   (United States)

ⁿ San Juan MBCCOP   (United States)

^o Southwest Oncology Group   (United States)

^p CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^q North Central Cancer Treatment Group Rochester   (United States)

^r UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^s WASHINGTON CANCER INSTITUTE   (United States)

^t AULTMAN HOSPITAL   (United States)

^u ALLEGHENY GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; ESTROGEN RECEPTOR; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; INTENTION TO TREAT ANALYSIS; JAW OSTEONECROSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; MULTICENTER STUDY; OVERALL SURVIVAL; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CLODRONIC ACID; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED;

EID: 84863109831     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70226-7     Document Type: Article

References (29)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005, 365:1617-1687. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
2. Smith R, Jiping W, Bryant J, Kay A, Paterson AG, Wolmark N Primary breast cancer (PBC) as a risk factor for bone recurrence (BR): NSABP experience. Proc Am Soc Clin Oncol 1999, 18. abstr 457.
3. Goldhirsch A, Gelber RD, Price KN, et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994, 343:377-381.
4. Fleisch H Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991, 42:919-944.
5. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995, 55:3551-3557.
6. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000, 88(12 suppl):2979-2988.
7. Clézardin P, Ebetino FH, Fournier PG Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005, 65:4971-4974.
8. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:59-65.
9. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996, 335:1785-1791. for the Protocol 19 Aredia Breast Cancer Study Group.
10. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology: International Bone and Cancer Study Group. J Clin Oncol 1998, 16:3890-3899.
11. Mundy GR, Yoneda T Bisphosphonates as anticancer drugs. N Engl J Med 1998, 339:398-400.
12. Mundy GR Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
13. Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction on loss of bone mineral density in women with operable breast cancer. J Natl Cancer Inst 1998, 90:704-708.
14. Diel IJ, Solomeyer EF, Costa SD, et al. Reduction in new metastases in breast cancer with oral clodronate treatment. N Engl J Med 1998, 339:357-363.
15. Powles T, Paterson S, Kanis JA, et al. Randomised, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219-3224.
16. Powles TJ, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006, 8:R13.
17. Saarto T, Vehmanen L, Virkkrunen P, Blomqvist C Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
18. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
19. Coleman RE, Marshall H, Cameron D, et al. Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011, 365:1396-1405.
20. Peto R, Peto J Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A 1972, 135(part 2):185-198.
21. Cox D Regression models and life tables (with discussion). J R Stat Soc Ser B 1972, 34:187-220.
22. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assn 1958, 53:457-481.
23. Grambsch P, Therneau TM Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
24. Gail M, Simon R Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985, 41:361-372.
25. Fine JP, Gray RJ A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
26. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998, 83:2266-2274.
27. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ, Riggs BL Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002, 17:172-178.
28. Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 2002, 143:74-83.
29. Nicks KM, Fowler TW, Akel NS, Perrien DS, Suva LJ, Gaddy D Bone turnover across the menopause transition: the role of gonadal inhibins. Ann NY Acad Sci 2010, 1192:153-160.